4-羟基-3,5-二硝基苯乙酸 | 10463-37-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-羟基-3,5-二硝基苯乙酸
• 中文别名: 3,5-二硝基-4-羟基苯基乙酸；3,5-二硝基-4-羟基苯乙酸
• 英文名称: 3,5-Dinitro-4-hydroxy-phenylessigsaeure
• 英文别名: (4-hydroxy-3,5-dinitro-phenyl)-acetic acid；(4-Hydroxy-3,5-dinitro-phenyl)-essigsaeure；3,5-Dinitro-4-hydroxyphenylacetic acid；2-(4-hydroxy-3,5-dinitrophenyl)acetic acid
• CAS: 10463-37-3
• 化学式: C₈H₆N₂O₇
• mdl: MFCD00016995
• 分子量: 242.145
• InChiKey: MLVYQQLUGFSXQH-UHFFFAOYSA-N

物化性质

• 熔点：
  166-168°C
• 沸点：
  417.3±40.0 °C(Predicted)
• 密度：
  1.742±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规格使用和储存则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  149
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2918290000

反应信息

• 作为反应物：
  描述：

  4-羟基-3,5-二硝基苯乙酸 在 tin(II) chloride dihdyrate 、 sodium cyanoborohydride 、 1-羟基苯并三唑 、 三乙胺 、 zinc(II) chloride 、 N,N'-二异丙基碳二亚胺 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 50.0h， 生成 N-benzyl-2-{4-hydroxy-3,5-bis[(thiophen-2-ylmethyl)amino]phenyl}acetamide
  参考文献：
  名称：

  Structural basis for the design and synthesis of selective HDAC inhibitors

  摘要：

  Histone Deacetylases are considered promising targets for cancer epigenetic therapy, and small molecules able to modulate their biological function have recently gained an increasing interest as potential anticancer agents. In spite of their potential application in cancer therapy, most HDAC inhibitors unselectively bind the several HDAC isoforms, giving rise to different side-effects. In this context, we have traced out the structural elements responsible of selective binding for the therapeutically relevant different HDAC isoforms. The structural analysis has been carried out by molecular modeling, docking in the binding pockets of HDAC1-4 and HDAC6-8, 36 inhibitors presenting a well defined selectivity for the different isoforms. As quick proof of evidence, we have designed, synthesized and experimentally tested three selective ligands. The experimental data suggest that the obtained structural guidelines can be useful tools for the rational design of new potent inhibitors against selected HDAC isoforms. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.036
• 作为产物：
  描述：

  3,5-Dinitro-4-hydroxy-benzylcyanid 在 硫酸 作用下， 生成 4-羟基-3,5-二硝基苯乙酸
  参考文献：
  名称：

  氟化氨甲酰胺衍生物的合成及其药理活性。

  摘要：

  DOI：

  10.1021/jm00342a019

文献信息

• [EN] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES<br/>[FR] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL-N-ARYL-BENZAMIDES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE CYTOKINES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005090333A1

  公开（公告）日：2005-09-29

  Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  公开的化合物式(I)，可以抑制与炎症过程有关的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理状况，如慢性炎症性疾病。还公开了制备这些化合物的方法以及包含这些化合物的药物组合物。
• Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: new anti-angiogenesis analogs
  作者：Alexandre Bridoux、Riaz A. Khan、Celei Chen、Gwenaël Chevé、Huadong Cui、Evgeny Dyskin、Aziz Yasri、Shaker A. Mousa

  DOI：10.3109/14756366.2011.557023

  日期：2011.12.1

  angiogenesis. OBJECTIVE Obtaining new transactivator, bifunctional, thyroid antagonist, non-toxic anti-angiogenic compounds. MATERIALS AND METHODS In silico drug design, synthesis in bulk and biological evaluation in chick chorioallantoic membrane (CAM) model. RESULTS Significant inhibition (range 65-73%) at 0.25-2.0 μg/ml doses. DISCUSSION AND CONCLUSION The synthesis of compounds (9), (10), and (11)

  背景技术抑制病理性血管生成。目的获得新型反式激活剂，双功能，甲状腺拮抗剂，无毒的抗血管生成化合物。材料和方法在鸡的绒毛尿囊膜（CAM）模型中进行计算机药物设计，批量合成和生物学评估。结果在0.25-2.0μg/ ml剂量下有明显的抑制作用（范围为65-73％）。讨论和结论合成了分别将长链部分的胍，尿素，甲胺和丙胺取代基掺入到四（四碘代乙酸）的核心分子框架中的化合物（9），（10）和（11）。承担。在CAM模型中对这些化合物的抗血管生成生物活性的评估表明，与tetrac和XT199相比，它们没有活性损失，后者在1和0剂量水平下显示出近86％的抑制作用。
• Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
  申请人：——

  公开号：US20040236111A1

  公开（公告）日：2004-11-25

  A dithiazole compound or a salt thereof expressed by formula (I): 1 wherein R 1 is hydrogen atom, alkyl, etc.; R 2 is hydrogen atom, hydroxy, alkyl, aryl, arylalkoxy, arylalkyl, etc.; R 3 is one group of formulae (II), (III) and (IV): 2 This compound has an excellent inhibiting action on matrix metalloprotease (MMPs) activity, and is useful for pharmaceutical, cosmetic and skin external compositions.

  一种由式（I）表示的二噻唑化合物或其盐：其中，R1是氢原子，烷基等；R2是氢原子，羟基，烷基，芳基，芳基烷氧基，芳基烷基等；R3是式（II），（III）和（IV）的一种基团：该化合物对基质金属蛋白酶（MMPs）活性具有出色的抑制作用，并且在制药，化妆品和皮肤外用组合物中非常有用。
• Anti-cytokine heterocyclic compounds
  申请人：Cogan Derek

  公开号：US20060079519A1

  公开（公告）日：2006-04-13

  Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  公开的式子为（I）的化合物，其抑制涉及炎症过程的细胞因子的产生，并因此有用于治疗涉及炎症的疾病和病理情况，如慢性炎症性疾病。还公开了制备这些化合物的过程和包含这些化合物的制药组合物。
• Anti-Cytokine Heterocyclic Compounds
  申请人：Cogan Derek

  公开号：US20070142371A1

  公开（公告）日：2007-06-21

  Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  公开了一种式子为(I)的化合物，可以抑制与炎症过程有关的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理情况，如慢性炎症性疾病。还公开了制备这些化合物和包含这些化合物的药物组合物的方法。